MedPath

Study of Immunity Dysfunction Induced by Extracorporeal Assistance (ECMO / ECLS)

Completed
Conditions
Acute Respiratory Distress Syndrome
Cardiogenic Shock
Interventions
Biological: Blood test
Registration Number
NCT03262155
Lead Sponsor
Rennes University Hospital
Brief Summary

Study of immunosuppression biomarkers in patients with ARDS or cardiogenic shock with ECMO / ECLS, compared to patients with ARDS or cardiogenic shock without ECMO / ECLS

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
18
Inclusion Criteria
  • Patient older than 18 years old
  • Patient hospitalized in an intensive care unit
  • Patient whose initial ARDS or Cardiogenic shock began less than 5 days before admission
  • Patients hospitalized for ARDS or Cardiogenic shock with ECMO / ECLS or - Patients hospitalized for ARDS or Cardiogenic shock without ECMO / ECLS
Exclusion Criteria
  • Opposition of patient, relative or legal representative for participation in the study
  • Pregnant woman
  • Pre-immunodepression
  • Implementation of immunosuppressive therapy such as chemotherapy, cyclophosphamide, high-dose corticosteroids (> 0.5mg / kg / day).

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
No ECMO / ECLSBlood testPatients hospitalized for ARDS or Cardiogenic shock without ECMO / ECLS
ECMO / ECLSBlood testPatients hospitalized for ARDS or Cardiogenic shock with ECMO / ECLS
Primary Outcome Measures
NameTimeMethod
Prevalence of immunosuppression in patients with ARDS or cardiogenic shock under ECMO / ECLS hospitalized in intensive care unitHour 24
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

CHU de Rennes

🇫🇷

Rennes, France

© Copyright 2025. All Rights Reserved by MedPath